Currently, GPx3 is considered a new tumor-suppressor gene [23], and its hypermethylation, which is associated with the further down-regulation of GPx3, was observed in patients with Barrett’s esophagus [54], endometrial adenocarcinoma [55] and prostate cancer [56]. This evidence concerns the gene GPX3 and esophageal adenocarcinoma.